CROI 2013: Adding Telaprevir Ups Acute Hepatitis C Cure Rate for HIV+ Men [VIDEO]


Adding telaprevir (Incivek) to pegylated interferon/ribavirin for treating HIV positive men with acute sexually transmitted hepatitis C considerably shortens the duration of therapy and improves the likelihood of a cure, according to study findings presented this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

It is well known that treating acute or recent HCV infection rather than waiting until the later chronic phase is associated with higher sustained response rates, for both HCV monoinfected and HIV/HCV coinfected people, and only takes half as long.

[Daniel Fierer speaks with Liz Highleyman about triple therapy for acute hepatitis C, CROI 2013, Atlanta, March 3, 2013]

Daniel Fierer from Mt. Sinai Medical Center in New York City performed a pilot study of acute treatment including the HCV protease inhibitor telaprevir.

Summarizing his results in an interview with on Sunday, Fierer said triple therapy during acute HCV infection can cut treatment length in half again and further increase response rates.



D Fierer. Telaprevir for Acute Hepatitis C Virus in HIV+ Men both Shortens Treatment and Improves Outcome. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 156LB.